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Hybrid capture II (HC II) test for oncogenic human papillomaviruses (HPV) was carried out in a cohort of
4284 women at their first clinical visit. Overall prevalence of HPV was 17.1%, decreasing with age from
33.9% among women below 20 years to only 11.0% among those older than 41 years. HPV prevalence was
significantly higher among current smokers (odds ratio [OR] ¼ 1.31; 95% CI 1.1–1.6), in women with two or
more lifetime sexual partners (OR ¼ 1.9; 95% CI 1.6–2.4), and those women with two or more sexual part-
ners during the past 12 months prior to examination (OR ¼ 1.6; 95% CI 1.2–2.2). HPV detection increased
in parallel with increasing cytologic abnormality, being highest in women with high-grade squamous intra-
epithelial lesion (P ¼ 0.001). Specificity of the HPV test in detecting histologically confirmed cervical dis-
ease was 85% (95% CI 83.9–86.1). Sensitivity of the HPV test in detecting histologic abnormalities increased
in parallel with disease severity, ranging from 51.5% for cervical intraepithelial neoplasia (CIN) 1 to 96.5%
for CIN 3 and 100.0% for cancer, with respective decline of positive predictive value. These data suggest
that HPV testing with HC II assay might be a viable screening tool among this population with relatively
high prevalence of cervical disease.
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In the recent literature, a variety of new strategies for
cervical cancer screening are heavily debated. There is
no doubt that the organized screening based on cervi-
cal cytology has resulted in dramatic reduction of inci-
dence and mortality of cervical cancer in countries
where implemented(1,2), despite the recognized limi-
tations of this diagnostic tool, ie, false-negative
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smears(3). According to the usual practice, women with
high-grade squamous intraepithelial lesion (HSIL) are
referred for colposcopy(4), while repeated smear is rec-
ommended in cases with mild cytologic abnormalities
atipy of squamous cells (ASC) or low-grade squamous
intraepithelial lesion (LSIL). Due to the fact that a)
ASC and LSIL are common findings (with only 10%
representing true high-grade lesions)(5), b) false-
positive tests result in substantial number of unneces-
sary colposcopies(4,6), and c) false-negative smears and
failure to detect high-grade lesions and even cancer,
this strategy is responsible for a heavy burden to the
public health care system.
Presence of high-risk human papillomaviruses (HPV)
is necessary for the development and persistence of
cervical intraepithelial neoplasia (CIN)(7,8). This has
prompted extensive testing of different HPV detection
assays as optional screening tools of cervical cancer.
Thus, addition of HPV testing to cytology has been
suggested to increase the sensitivity and negative pre-
dictive values (NPV) for high-grade cervical lesions,
therefore, prolonging the screening intervals and
reducing referrals for colposcopy(9–12), making HPV
testing also a cost-effective option(13). Based on these
favorable recent data, national guidelines, eg, in United
States now allow the combined use of HPV testing
and cytology in the primary screening of women 30
years or older(14,15). In several European countries, the
incorporation of HPV testing in cervical cancer screen-
ing is currently under discussion(16,17).
Incidence of cervical cancer in Latin America is
among the highest worldwide(18). However, disease
burden in this large continent is unevenly distributed,
being dependent upon the screening practices in the
different regions. These range from practical non-
availability to relatively well-organized programs,
most notably in the urban centers of the south of the
continent. The authors recently designed a multicenter
study to test eight different screening tools in a cohort
of over 12,000 women enrolled by four clinics in re-
gions of Brazil and Argentina with different incidence
of cervical cancer, known as the Latin American Screen-
ing (LAMS) study(19). One of the two major aims of this
study is to find out the cost-effective tools for cervical
cancer screening in these low-resource settings.
HPV testing using commercially available hybrid
capture II (HC II) is one of the eight tools included in
the LAMS study(19). The present communication re-
ports our experience with the use of HC II assay in
over 4000 Brazilian and Argentinean women and criti-
cally weights the possible utility of this assay in cervi-
cal cancer screening, in regions with relatively high
incidence of cervical disease.
Materials and methods
Study design
LAMS study is an ongoing prospective multicenter
study, supported by the European Commission
through its International Cooperation for Development
Countries (INCO-DEV) Program (ICA4-CT2001-
10013)(19). In this study, 12,114 consecutive women
from the cities of Campinas (Brazil), Sa˜o Paulo (Brazil),
Porto Alegre (Brazil), and Buenos Aires (Argentina)
were recruited to undergo gynecological examination
and testing with conventional Papanicolaou (Pap)
smear, visual inspection with acetic acid (VIA), visual
inspection with Lugol´s iodine (VILI), cervicography,
and screening colposcopy. Women were sampled for
HPV testing by HC II. To ensure high reproducibility of
the testing, specialist gynecologists carried out exami-
nations in all centers and well-trained nurses took care
of the specimen collection for HC II and Pap. All
enrolled women gave their agreement to participate by
signing the informed consent, written in their native
language. The study protocol has been approved by the
local ethics committees of all four participating clinics.
Women were considered eligible if they met all of
the following requirements: a) had an intact uterus (ie,
no previous surgical procedure of the cervix or cor-
pus); b) had no history of abnormal Pap test in the
past year; c) were not under treatment for genital con-
dyloma (external or in the cervix); d) had no sexual
intercourse during the 3 days prior to the examination;
and e) did not have any confirmed or clinically suspect
immunosuppression (human immunodeficiency virus,
corticosteroids, chemotherapy) or other chronic disea-
ses that might compromise the immune system.
Flowchart of the patient examination is shown in
Figure 1. At the first visit, all women were subjected to
a questionnaire addressing clinical and epidemiologic
risk factors of cervical neoplasia. All women were sub-
jected to a thorough pelvic examination, comprising
collection of the Pap smear, HC II sampling, and VIA
or VILI (data not shown). Women who had at least
one of these examinations abnormal were referred to
colposcopic examination. Also, to control for verifica-
tion bias, 5% of the women with all screening tests
negative were randomly assigned for colposcopy and
all (802 women) who attended consultations at Cam-
pinas State University Hospital were subjected to col-
poscopy. Whenever colposcopy revealed an abnormal
pattern, a directed punch biopsy was taken(19). Women
had their second visit scheduled after 45 days, to be-
come informed about their exam/biopsy results and
to be allotted to either the treatment or the follow-up
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group. Treatment was offered in accordance to the
routine practices adopted by the participating centers.
Study centers and demographics
Campinas (Brazil) is a 1 million inhabitants city, situ-
ated in southeast region of the country, approximately
100 km from Sa˜o Paulo city. The city is a dynamic
commercial and industrial center, with a relatively
well-structured health system and some high-standard
hospitals. However, a substantial portion (almost 20%)
of its population, living in the outskirts of the city, is
composed of people who migrated from the north and
northeast (the poorest) regions of the country, search-
ing for jobs. In Sa˜o Paulo state, encompassing the cit-
ies of Campinas and Sa˜o Paulo, cervical cancer is the
fourth major cause of cancer death among women,
accounting for 3.3% of all female deaths due to cancer.
In this region, breast cancer accounted for 13.3% of
cancer deaths among women between 1995 and
1999(15). Women have been enrolled in the Centro de
Atencxa˜o Integral a` Sau´de da Mulher, a State Univer-
sity of Campinas’ teaching hospital, dedicated to
women care and in a basic health unit in the outskirts
of the city. Sa˜o Paulo city is the economic powerhouse
of Brazil, with 11 million inhabitants. Its population is
composed of a multiple ethnic groups (European
whites, Asians, and Afro-Americans). Health care is
heterogeneous, ranging from overcrowded public
basic health units and hospitals to a high-quality pri-
vate sector. In this city, women have been enrolled by
Hospital Leonor Mendes de Barros, a public institu-
tion that performs over 50,000 gynecological and
obstetric consultations every year. Porto Alegre
(Brazil) is the capital of Rio Grande do Sul State, in the
south of the country. The state’s population enjoys the
best levels of quality of life in the country although
cervical cancer is the sixth major cause of cancer death
among women, accounting for 6.10% of all female
deaths due to cancer. In this region, breast cancer
accounted for 15.1% of cancer deaths among women
from 1995 to 1999(15). The participant center was Hos-
pital de Clı´nicas de Porto Alegre, a general hospital
affiliated to Federal University of Rio Grande do Sul.
The Department of Obstetrics and Gynecology of this
center is responsible for roughly 30,000 gynecological
and obstetric consultations per year. Buenos Aires is
the capital of Argentina, and the participating center
in this country was Hospital de Clı´nicas Jose´ de San
Martin, a general teaching hospital with large experi-
ence in gynecology and obstetrics and being a refer-
ence center for colposcopy for the entire country. The
country has an overall cervical cancer mortality rate of
7.6 per 100,000 women(16).
Examinations
Cervical cytology (Pap smear)
Conventional Pap smears were taken using the Ayre
spatula and endocervical brush, fixed in 95% ethanol, and
stained by the modified Pap method. For liquid-based
Figure 1. Flowchart of the examinations and their results.
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cytology, a direct-to-vial protocol was followed (DNA-
Citoliq System, Digene, Sa˜o Paulo, Brazil;
and AutocytePREP, TriPath Imaging, Burlington,
NC). Final cytologic diagnoses were issued by the
Bethesda 2001 System(20) and were classified as
normal/inflammatory, ASC, atypical glandular cells,
LSIL, or HSIL.
Hybrid capture II (HC II)
Altogether, 4284 women were tested with HC II at
their first clinical visit. The specimens for HC II were
tested with probe B (high-risk HPVs: types 16, 18, 31,
33, 35, 39, 45, 51, 52, 56, 58, 59, and 68)(21), and the
tests were classified positive at the relative light unit/
positive control (RLU/CO) ratio of 1 pg/mL or
greater. These RLU/CO ratios provide a semi-
quantitative estimate of the amount of HPV DNA in
the specimens, ie, the viral load in the sample. Storage
of specimens and reagents, as well as test processing,
was carried out in manufacturer-certified laboratories,
under the responsibility of the investigators, following
the manufacturer’s instructions (Digene Co. Gaithers-
burg, MD). Sa˜o Paulo (Brazil) and Buenos Aires
(Argentina) processed their own HC II samples in-
house, while Campinas (Brazil) and Porto Alegre
(Brazil) had their HC II specimens processed at a Cam-
pinas University Hospital laboratory.
Cervical biopsies
Directed punch biopsies (and cone biopsies) were
fixed in formalin, embedded in paraffin, and pro-
cessed into 5-lm-thick sections stained with hematox-
ylin and eosin for light microscopy, following the
routine procedures. All biopsies were examined
among the daily routine in the Pathology Departments
of the four clinics and diagnosed using the commonly
agreed CIN nomenclature. For the study purposes, the
pathologists were also asked to notify the morphologic
changes suggestive for the presence of HPV in cases
with no CIN (flat condyloma).
Statistical analysis
Possible differences regarding patients’ age distribu-
tion between study centers were tested with the paired
t test. After testing age distribution for normality with
Shapiro–Wilk’s test (normality has been ruled-out),
age differences across the strata were assessed with
nonparametric tests (Wilcoxon’s rank sum test). Logis-
tic regression analysis was used to calculate odds ratio
(OR) for HC II positivity related to the recorded epide-
miologic variables, as well as to cytologic (Pap smear)
or histologic results. The 95% confidence intervals
(95% CI) were calculated for all data using the accu-
rate methods(22).
Results
Mean age of the patients was 37.5 years (90% central
range 20.4–55.4 years). Overall prevalence of HPV was
17.1%. Mean age of women with positive HC II (33.6
years) was significantly lower than that of women
with a negative HPV test (38.3 years; P , 0.0001).
HPV prevalence decreased with age, ranging from
33.9% among women younger than 20 years to only
11.0% among those aged 41 years or more, with no
difference between the studied four populations (P ¼
0.90; Table 1).
HPV detection related to key epidemiologic charac-
teristics of the patients is shown in Table 2. Current
smoking was marginally related with HPV infection
(OR ¼ 1.31; 95% CI 1.1–1.6). As compared to women
who had only one lifetime sexual partner, women
with two to four lifetime sexual partners (OR ¼ 1.9;
95% CI 1.6–2.4) and those who had five or more sex-
ual partners (OR ¼ 2.7; 95% CI 2.1–3.5) presented with
Table 1. Age-related detectiona of HPV in the four clinics
Age (years)
Clinicb
Sa˜o Paulo,
Positive/total (%)
Campinas,
Positive/total (%)
Porto Alegre,
Positive/total (%)
Buenos Aires,
Positive/total (%)
Total,
Positive/total (%)
20 2/18 (11.0) 42/127 (33.1) 14/25 (56.0) 3/10 (30.0) 61/180 (33.9)
21–30 50/187 (26.7) 115/463 (24.8) 43/156 (27.6) 56/264 (21.2) 264/1070 (24.7)
31–40 38/253 (15.0) 64/389 (16.5) 50/304 (16.4) 53/258 (20.5) 205/1204 (17.0)
41 43/348 (12.4) 49/457 (10.7) 63/618 (10.2) 47/408 (11.5) 202/1830 (11.0)
Totalc 133/806 (16.5) 270/1436 (18.8) 170/1103 (15.4) 159/940 (16.9) 732/4284 (17.1)
aHC II. ¼ 1.0 RLU/CO.
bComparing study centers: P ¼ 0.90 (excluding patients 20 years old or younger).
cMean age of women with positive HC II (33.6 years) was significantly lower than that of women with a negative HPV test (38.3
years, P , 0.0001).
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a significantly higher HPV prevalence. HPV was also
more prevalent among women with two or more sex-
ual partners during the past 12 months prior to con-
sultation, as compared with women who had no or
only one sexual partner (OR ¼ 1.6; 95% CI 1.2–2.2).
Parity, being pregnant at the time of testing, and cur-
rent use of oral contraceptives did not show any rela-
tion to HPV positivity.
Table 3 shows HPV detection rates in women with
different Pap smear abnormalities. ORs increased in
parallel with progressive cytologic abnormalities: ASC
(OR ¼ 2.9; 95% CI 2.4–3.5), LSIL (OR ¼ 21.4; 95% CI
10.8–43.1), and HSIL (OR ¼ 75.6; 95% CI 22.3–307.2).
Only six women were diagnosed with glandular
abnormalities in cytology, which were not statistically
associated with increased HPV detection (OR ¼ 6.0;
95% CI 0.9–37.0).
HPV detection is related to histologic diagnosis
(Table 4). Fifteen percent of women with no detectable
disease had a positive HC II test, making the test spe-
cific at the level of 85% (95% CI 83.9%–86.1%). HPV
prevalence increased in parallel with increasing grade
of the lesions, ending up with 100% in invasive carci-
nomas (P , 0.001). Sensitivity of the HPV test to histo-
logic abnormalities increased in parallel with disease
severity, ranging from 51.5% for CIN 1 to 96.5% for
CIN 3 and 100.0% for cancer.
Discussion
Recent developments in understanding the natural
history of cervical cancer and its precursors as well as
the rapid development of novel technologies are chal-
lenging the traditional concepts of cervical cancer
screening. Until now, most studies addressing HPV
detection as a screening tool have been carried out in
developed countries, where prevalence of cervical
abnormalities has been modified by several years of
well-conducted screening programs using cervical
cytology(23–25,13). The ongoing LAMS study is one of
the first multicenter efforts conducted in developing
countries(19), thus, providing important insights into
the utility of HC II testing in populations in low-
resource settings.
In alignment with most of the previous reports, HC
II assay is highly sensitive for high-grade cervical dis-
ease. Of 29 women with CIN 3, only 1 was HPV nega-
tive and all the 4 cases of cancer had a positive HPV
test. The likelihood of a woman with negative HPV
testing to harbor a high-grade cervical lesion is
extremely low, and thus, the NPVof HPV testing is ex-
pected to be very high(24,26). Solid confirmation of
these findings has been provided by the Population
Based Screening Study Amsterdam (POBASCAM) in
which 44,102 women were tested for high-risk HPV
types using polymerase chain reaction (PCR)(25). In the
intervention group (women subjected to HPV testing
plus cytology) of this population-based controlled
Table 2. HPV detection related to key characteristics of the
patients
Characteristic
HC II
Adjusteda
OR(95% CI)
Positive,
n (%)
Negative,
n (%)
Age (years)
20 61 (8.3) 119 (3.4) 4.4 (3.1–6.5)
21–30 264 (36.1) 806 (22.7) 2.3 (1.8–2.9)
31–40 205 (28.0) 999 (28.1) 1.5 (1.2–1.9)
41 202 (27.6) 1628 (45.8) Referential
Current smoker
Yes 206 (28.1) 765 (21.5) 1.3 (1.1–1.6)
No 526 (71.9) 2787 (78.5) Referential
Oral contraceptives
Yes 271 (37.1) 1100 (31) 1.2 (0.9–1.4)
No 459 (62.9) 2452 (69) Referential
Parity
0 339 (46.3) 1396 (39.3) Referential
1–2 263 (35.9) 1368 (38.5) 1.0 (0.8–1.2)
3 or more 130 (17.8) 792 (22.3) 1.1 (0.9–1.5)
Currently pregnant
Yes 20 (2.7) 58 (1.6) 1.2 (0.7–2.0)
No 692 (94.5) 3437 (96.6) Referential
Lifetime sexual
partners
1 181 (24.7) 1555 (43.7) Referential
2–4 385 (52.6) 1553 (43.7) 1.9 (1.6–2.4)
5 166 (22.7) 449 (12.6) 2.7 (2.1–3.5)
Sexual partners
during past
12 months
0 or 1 656 (89.6) 3422 (96.2) Referential
2 76 (10.4) 136 (3.8) 1.6 (1.2–2.2)
aLogistic regression.
Table 3. HPV detection as related to Pap smear abnormalities
Pap smear
HC II
Positive,
n (%)
Negative,
n (%) OR 95% CI
Normal 582 (14.5) 3442 (85.5) Ref
ASC 65 (41.6) 91 (58.4) 2.9 2.4–3.5
LSIL 43 (78.2) 12 (21.8) 21.4 10.8–43.1
HSIL 38 (92.7) 3 (7.3) 75.6 22.3–307.2
AGC 3 (50.0) 3 (50.0) 6.0 0.9–37.0
Invasive
carcinomas*
1 (50.0) 1 (50.0) n/a n/a
Total 732 (17.1) 3552 (82.9) — —
AGC, atypical glandular cells.
*P , 0.001.
n/a ¼ not available.
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trial, 96.7% (89 out of 92 cases) of women diagnosed
with CIN 3 or worse lesions had a positive HPV
test. The comparisons of LAMS study data and
POBASCAM study, however, should be taken with
caution because POBASCAM is a population-based
trial, and the women invited for LAMS cohort study
should be free of HPV-induced disease at least for 1
year. This conceptual difference between both pop-
ulations can explain, in part, the overall HPV preva-
lences: 5% in POBASCAM study, contrasting to the
17.1% of the present series. We can hypothesize if this
marked difference in HPV prevalence portrays any
substantial differences in the risk of cervical cancer
between the populations studied by POBASCAM(25)
and in the LAMS study, the Dutch and Latin Ameri-
can women, respectively. These risk discrepancies,
clearly favoring the Dutch population, is a mere reflec-
tion of the epidemiologic factors involved with HPV
infection. Mean age at first intercourse, number of sex-
ual partners, and parity, directly addressed in this
study, are known to be, by data reported on several
population series, dramatically disadvantageous to
Latin American populations as compared to Western
European ones.
Another interesting feature in comparing the LAMS
and the POBASCAM studies was the marked similar-
ity in the prevalence of cytologic abnormalities as
related to the HPV status. In the LAMS cohort, 79.5%
(582/732) of the women with positive HPV test
showed a normal cytology, the corresponding figure
in the POBASCAM study being 69.4%(25). Accord-
ingly, borderline and mild dyskaryosis were found in
16.8% of the HPV-positive POBASCAM population,
being almost identical with that (14.9%) of ASC/LSIL
in the present series. However, 13.7% of the HPV-posi-
tive POBASCAM women had HSIL, as contrasted to
only 5.2% in the present series. Ultimately, the preva-
lence of histologically confirmed cervical disease in
the LAMS study is almost fivefold higher than that in
the POBASCAM study(25). This cannot be due to the
different performance of HC II and PCR used in the
LAMS and POBASCAM study, respectively, because
there seem to be no differences. It should be noted that
the HPV positivity for CIN 3 lesions in the PO-
BASCAM study was 96.7% and in this study 96.5%. It
is noteworthy that no glandular lesions (ie, in situ or
invasive adenocarcinoma) were found in the present
series, even though there were six cases of glandular
abnormalities in Pap smears. Although the viral types
included in both tests are almost identical (only HPV
66 is detected by HC II but not by the PCR), PCR is
usually more analytically sensitive than HC II; how-
ever, the clinical sensitivity of HC II is usually at least
equal to that of PCR(25). Therefore, for the women of
LAMS cohort had not being properly triaged before
and for the socioeconomic unfavorable circumstances
in which these women live, high prevalence of HPV
might had led to an augmented prevalence of actual
HPV-related disease. It is possible to speculate that
immunologic factors, related to impoverished living
conditions, smoking habits, and inadequate triaging
and treatment of vaginal infections, probably favored
the development of disease in HPV-infected women.
The adoption of any new screening tool and practice
should be matched with the local cost environment,
expertise, and existing facilities. This fact has been
well recognized recently and has prompted research-
ers to design and implement studies aimed at testing
different optional screening tools that are affordable in
the local settings of their implementation. For instance,
most studies on visual inspection of the cervix (VIA or
VILI) have been conducted in India and Africa, where
cervical disease is highly prevalent and limitations of
resources are dramatic(27,28). The regions of Brazil and
Argentina, where this study is being carried out do
not equal in disease burden with the Indian and Afri-
can settings used to test these two visual methods.
However, they do have higher prevalence of cervical
cancer than most European and North American
countries, where most of the studies on HPV testing
have been conducted(27,28). This fact probably makes
the present results applicable for all the settings, facing
Table 4. HPV detection as related to histologically confirmed cervical pathology
Final diagnosis
HPV DNA
Positive, n (%) Negative, n (%) Sensitivity (95% CI) Specificity (95% CI) PPV (%) NPV (%)
No disease 644 (15.0) 3508 (85.0) — 85% (83.9–86.1) — 97.1
HPV/CIN 1 35 (51.5) 33 (48.5) 51.5% (39.6–63.3) 5.4 —
CIN 2 21 (67.7) 10 (33.3) 67.7% (61.3–84.2) 3.3 —
CIN 3 28 (96.5) 1 (3.5) 96.5% (89.9–100.0) 4.3 —
Invasive carcinomas* 4 (100.0) 0 (0.0) 100.0% (100.0–100.0) 0.7 —
Total 732 (100.0) 3552 (100.0) — — —
*P , 0.001.
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a transition between an underdeveloped and a devel-
oped world. Indeed, such settings can be encountered
in several regions of South America and Asia.
Currently, cost-effectiveness is one of the major con-
cerns of health authorities planning public health pro-
grams. In countries with high living standards, such
as the UK, the Netherlands, France, and Italy, screen-
ing with HPV testing has been proven cost-effective
in a recently published study(13). Those researchers
concluded that HPV DNA testing has the potential to
improve health benefits at a reasonable cost in the
aforementioned countries, with an overall incremental
cost of $13,000 per year of life saved. This incremental
cost is believed unacceptable for a majority of the de-
veloping countries, especially with regard to government-
funded programs.
Unfortunately, to compare the costs of the current
Brazilian public health system reimbursement for Pap
smear with HC II is not possible because the Brazilian
government does not reimburse HC II yet. Currently,
the reimbursement for Pap smear for hospitals and
laboratories is R$5.37, which is approximately US$2.0
for each cervical Pap smear performed. The cost of HC
II in Brazil is approximately U$7–U$8 for public sector
screening projects. Nowadays, the use of HC II in
Latin America is strictly tied to the private health
assurance sector that is free to stipulate the value to be
reimbursed. Indeed, this fact limits the use of HC II, as
recently discussed(19).
Regardless of these cost restrictions, high prevalence
of HPV in the present cohort results in the extremely
low positive predictive value (PPV) of the HC II test.
PPV along with NPV is believed to be crucial parame-
ters to screening of any disease. It is widely regarded
that the observed PPV should be a reflection of the
tests performance characteristics in providing an
acceptable false-positive rate and an NPV with robust
potential to avoid an unacceptable false-negative rate.
In other words, test performance characteristics in
terms of PPV and NPV need to meet an acceptable
compromise(29). This is true for Latin America where
we have a high prevalence of histologically confirmed
disease. If we consider that in the past three decades,
the rates of morbidity and mortality for cervical cancer
did not change in many regions of Brazil for several
reasons, sensitivity and NPV should be taken into
account as important parameter to prevent disease
and to select women for specific tools to recognize dis-
ease. Actually, to overcome this major shortcoming of
the HC II assay and to take the full advantage of the
high sensitivity of the test, the most reasonable
approach is to combine cytology and HPV testing.
Indeed, combined use of cytology and HPV testing is
the rationale of the current recommendations for the
HPV test usage in the United States(14). A negative
HPV result together with normal cytology renders the
women eligible for the next screening round after 3
years or more, resulting in a considerable reduction in
the number of medical consultations. Conversely,
a positive HPV test alone shall not mandate a colpo-
scopic examination in populations with high preva-
lence of HPV(4,14), such as the LAMS study cohort.
As suggested in several studies, women aged 30
years or more would be the appropriate targets of
HPV-based screening strategies(4,14). This also applies
to the LAMS study cohort if HPV testing is coupled to
a reflex cytology test. Roughly, 14% of women in the
higher age groups were HPV positive in this study,
which therefore precludes any possible usage of HPV
testing in this population as a stand-alone screening
tool, with immediate referral of positive women to
colposcopy because of the obvious overload of colpo-
scopy referrals inevitably resulting from such a policy.
Current research on cervical screening is being
focused on innovative use of traditional and novel
diagnostic tools(24,27,28). For the moment, there does
not seem to be any stand-alone test capable of deliver-
ing optimal sensitivity combined with good predictive
values. Therefore, combined use of available diagnos-
tic tools shall be considered, while planning novel
screening strategies. In this planning, the designers
need to be aware of the weaknesses and strengths of
each individual test, as related to their performance in
the target populations to be screened. This study pro-
vides some insights into the performance of HPV
testing (with an Food and Drug Administration
(USA)-approved commercially available HC II assay)
in a population with a relatively high prevalence of
HPV-related cervical disease. Screening strategies opti-
mally tailored for different public health environments
critically depend on testing of several optional diag-
nostic tools under field conditions, as done in the
ongoing LAMS study.
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